Menu
Subscribe - Individual
Subscribe - Biotech Premium (Corporate)
Home
About Us
Subscribe
Subscribe Individual
Subscribe Biotech Premium (Corporate)
Premium Biotech Coverage
Current News
Special Features
Company Index
Index Table
Summit
19th Bioshares Biotech Summit
Summit History
Contact
Contact Us
Email Alerts
Categories
Categories
Actinogen (ACW)
Adalta (1AD)
Amplia Therapeutics (ATX)
Anteris Technologies (AVR)
Aroa Biosurgery (ARX)
Blinklab (BB1)
Blog
Botanix (BOT)
Chimeric Therapeutics (CHM)
Clever Culture Systems (CC5)
Clinuvel Pharmaceuticals (CUV)
Cogstate (CGS)
Dimerix (DXB)
EBR Systems (EBR)
Immuron (IMC)
Imugene (IMU)
Island Pharmaceuticals (ILA)
Neuren Pharmaceuticals (NEU)
Patrys (PAB)
Syntara (SNT) (previously Pharmaxis, PXS)
Uncategorized
July 11th, 2025
Syntara Phase II Myelofibrosis Data Continues to Get Better
Read More
March 26th, 2025
Syntara Accelerates Wound Healing Program
Read More
October 3rd, 2023
Pharmaxis (Syntara) Sells off Mannitol Business
Read More
August 11th, 2023
Pharmaxis - Meaningful Impact on Bone Marrow in Myelofibrosis Study
Read More
June 6th, 2023
Mixed Results from Pharmaxis' Scar Treatment Study
Read More
May 1st, 2023
Pharmaxis Phase II Trial Results Approaching
Read More
February 24th, 2023
Pharmaxis: A Re-Rating Approaching?
Read More
December 23rd, 2022
Top 6 Stock Picks for 2023
Read More
November 4th, 2022
Pharmaxis Releases Initial Data in Myelofibrosis
Read More
October 5th, 2022
Pharmaxis - Encouraging Early Data from Scar Removal Study
Read More
September 19th, 2022
Pharmaxis: Can PXS-6302 'Un-scar the Scar'?
Read More
September 19th, 2022
Pharmaxis: Can PXS-6302 'Un-scar the Scar'?
Read More
September 9th, 2022
Pharmaxis Repurposes PXS-4728 for Parkinson's Disease
Read More
August 5th, 2022
Pharmaxis Sells Orbital Technology for US$5 Million
Read More
February 14th, 2022
Pharmaxis Update
Read More
Pages
1
